/KZIA
KZIA Stock - Kazia Therapeutics Limited
Healthcare|BiotechnologyNASDAQ
$10.87+8.92%
+$0.89 (+8.92%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.53
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+74.8%upside
Target: $19.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KZIA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$10.76 – $10.98
TARGET (TP)$19.00
STOP LOSS$10.00
RISK/REWARD1:9.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.68
52W High$17.40
52W Low$2.86
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $42,000 | $2.31M | $555 | $10,000 | $15.18M |
| Gross Profit | $42,000 | $2.31M | $555 | $10,000 | $15.18M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-14,217,000 | $-28,462,000 | $-24,123,969 | $-25,399,000 | $-6,376,000 |
| Net Income | $-20,702,000 | $-26,778,000 | $-20,465,180 | $-25,014,000 | $-8,420,000 |
| Net Margin | -49290.5% | -1160.2% | -3687419.8% | -250140.0% | -55.5% |
| EPS | $-18.90 | $-55.00 | $-55.00 | $-95.00 | $-35.80 |
Company Overview
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$3
Average Target
↓ 72.4% Downside
Now
$3
Low
$3
Average
$3
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 6th 2025 | Maxim Group | Initiation | Buy | $3 |
Earnings History & Surprises
KZIABeat Rate
86%
Last 7 quarters
Avg Surprise
-847.8%
EPS vs Estimate
Beats / Misses
6/1
Last 12 quarters
Latest EPS
$-0.43
Q4 2025
EPS Surprise History
Q3 21
+99.5%
$-0.01vs$-2.30
Q1 22
No data
Q4 22
+99.8%
$-0.06vs$-29.93
Q1 23
+99.7%
$-0.06vs$-24.65
Q4 23
+98.8%
$-0.02vs$-1.66
Q1 24
No data
Q4 24
+99.7%
$-0.04vs$-15.00
Q4 25
-6529.9%
$-0.43vs$-0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 6, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.01 | $-0.43 | -6529.9% | ✗ MISS |
Q2 2025 | May 28, 2025 | — | — | — | — |
Q4 2024 | Nov 19, 2024 | $-15.00 | $-0.04 | +99.7% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | — | $-0.03 | — | — |
Q4 2023 | Nov 27, 2023 | $-1.66 | $-0.02 | +98.8% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-24.65 | $-0.06 | +99.7% | ✓ BEAT |
Q4 2022 | Oct 6, 2022 | $-29.93 | $-0.06 | +99.8% | ✓ BEAT |
Q1 2022 | Jan 6, 2022 | — | $-0.07 | — | — |
Q3 2021 | Sep 30, 2021 | $-2.30 | $-0.01 | +99.5% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | $-2.30 | $-0.05 | +98.0% | ✓ BEAT |
Q4 2020 | Oct 22, 2020 | — | $-0.05 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.06 | — | — |
Q4 2019 | Oct 21, 2019 | — | $-0.05 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.08 | — | — |
Q4 2018 | Oct 24, 2018 | — | $-0.09 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.01 | — | — |
Q3 2017 | Aug 30, 2017 | — | $-0.10 | — | — |
Q1 2017 | Feb 22, 2017 | — | $-0.06 | — | — |
Q3 2016 | Aug 30, 2016 | — | $-0.14 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Kazia Therapeutics, Raises Price Target to $18
📈 PositiveBenzinga•Dec 12, 2025, 11:19 AM
Kazia Therapeutics shares are trading higher after the company announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium supporting the activity of paxalisib across both HER2-positive metastatic breast cancer and triple-negative breast cancer.
📈 PositiveBenzinga•Dec 11, 2025, 02:01 PM
Kazia Therapeutics Says First Patient From TNBC Trial Demonstrated 76% Tumor Volume Shrinkage With Corresponding Reductions In CTC And Clusters
📈 PositiveBenzinga•Dec 10, 2025, 01:07 PM
Kazia Therapeutics Shares Resume Trade Following Circuit Breaker Halt
➖ NeutralBenzinga•Dec 2, 2025, 02:44 PM
Kazia Therapeutics Announces ~$50M PIPE, Selling Ordinary Shares And Pre-Funded Warrants At A Price Equivalent To $5.00 Per ADS, Each ADS Representing 500 Ordinary Shares, With Expected Net Proceeds Of ~$46.5M
📈 PositiveBenzinga•Dec 2, 2025, 02:06 PM
Kazia Therapeutics shares are trading higher after the company reported an initial immune-complete response in a stage IV triple-negative breast cancer patient treated under an FDA-authorized expanded access protocol combining paxalisib with pembrolizumab and chemotherapy.
📈 PositiveBenzinga•Nov 19, 2025, 01:44 PM
Market-Moving News for November 19th
➖ NeutralBenzinga•Nov 19, 2025, 12:21 PM•Also: ,
Kazia Therapeutics shares are trading higher after the company reported an initial immune-complete response in a stage IV triple-negative breast cancer patient treated under an FDA-authorized expanded access protocol combining paxalisib with pembrolizumab and chemotherapy.
📈 PositiveBenzinga•Nov 18, 2025, 09:19 PM
Kazia Therapeutics Says Patient With Stage IV Triple-Negative Breast Cancer Achieved Initial Immune complete Response when Treated Under Protocol Of Paxalisib With Pembrolizumab And Standard Chemotherapy
📈 PositiveBenzinga•Nov 18, 2025, 09:18 PM
Kazia Therapeutics Intends To Request And Hold Follow-Up Type C Meeting With FDA To Discuss OS Findings In Newly Diagnosed Glioblastoma Patients Treated With Paxalisib
➖ NeutralBenzinga•Oct 27, 2025, 11:20 AM
Kazia Therapeutics Enters Exclusive Collaboration And In-Licensing Agreement With QIMR Berghofer For First-In-Class PD-L1 Degrader Program
📈 PositiveBenzinga•Oct 7, 2025, 12:42 PM
Maxim Group Maintains Buy on Kazia Therapeutics, Raises Price Target to $20
📈 PositiveBenzinga•Oct 2, 2025, 03:15 PM
KZIA stock has given up its prior gain. Kazia Therapeutics shares were trading higher after the company reported an 86% tumor burden reduction in a triple-negative breast cancer patient treated with paxalisib in combination regimen.
➖ NeutralBenzinga•Oct 2, 2025, 01:13 PM
Kazia Therapeutics shares are trading higher after the company reported an 86% tumor burden reduction in a triple-negative breast cancer patient treated with paxalisib in combination regimen.
📈 PositiveBenzinga•Oct 2, 2025, 12:37 PM
Kazia Therapeutics Reports Reduction In Tumor Burden From A Single-Patient Expanded Access Case In Triple-Negative Breast Cancer Treated With A Combination Regimen That Included The Co's Investigational pan-PI3K/mTOR Inhibitor, Paxalisib; After 3-Weeks Of Combination Immunotherapy/Chemotherapy Plus Paxalisib, Imaging Performed At The Treating Institution Showed An 86% Reduction In Overall Tumor Burden
📈 PositiveBenzinga•Oct 2, 2025, 12:36 PM
Kazia Therapeutics Announces Its Participation In A Fully Funded Australian Medical Research Future Fund Project Titled "Sequential & Temporal Therapeutic Agility For The Treatment Of Diffuse Midline Glioma"
📈 PositiveBenzinga•Oct 1, 2025, 01:23 PM
Kazia Therapeutics' Paxalisib Shows Complete Disruption Of Metastatic Cell Clusters In Stage IV HER2-Positive Breast Cancer Study
📈 PositiveBenzinga•Sep 11, 2025, 12:05 PM
Frequently Asked Questions about KZIA
What is KZIA's current stock price?
Kazia Therapeutics Limited (KZIA) is currently trading at $10.87 per share. The stock has moved +8.92% today.
What is the analyst price target for KZIA?
The average analyst price target for KZIA is $19.00, based on 1 analyst.
What sector is Kazia Therapeutics Limited in?
Kazia Therapeutics Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KZIA's market cap?
Kazia Therapeutics Limited has a market capitalization of $0.02 billion, making it a small-cap company.
Does KZIA pay dividends?
No, Kazia Therapeutics Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBDRX
Biodexa Pharmaceuticals Plc
$3.64
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CMND
Clearmind Medicine Inc.
$2.74
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
GRI
GRI Bio, Inc.
$0.34
Mkt Cap: $0.0B
INM
InMed Pharmaceuticals Inc.
$1.19
Mkt Cap: $0.0B
OGEN
Oragenics, Inc.
$0.88
Mkt Cap: $0.0B
SILO
Silo Pharma, Inc.
$0.38
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
TTNP
Titan Pharmaceuticals, Inc.
$2.34
Mkt Cap: $0.0B
Explore stocks similar to KZIA for comparison